Table 4. Adverse effects and Dropout rates from the included studies.

Author	Tolerability	Adverse Effects (AE) Reported	Dropout Rate n (%)
Cameron, 2014	Two patients had psychotic episode, but one was able to restart with no recurrence. Patients with pre-existing psychosis remained with routine anti-psychotic medications.	Psychosis, sedation, dry mouth, feeling “stoned”, orthostatic hypotension, agitation, headache	N = 31 (29.8%) reported adverse effects. N = 20 (19%) withdrew from the trial; n = 10 (9.6%) withdrew from the trial due to AE; n = 4 abuse of other medications; n = 2 residential facility did not allow cannabis use; n = 2 did not want to continue; n = 1 due to inefficacy; n = 1 had no coverage.
Chan, 2017	Most patients had mild to moderate AE	Dry mouth, Psycho-active effects (feeling “high”), Sleepiness, Red/irritated eyes, Heart palpitations, Decreased memory	NR
Drost, 2017	12.3% patients had deterioration in PTSD symptoms.	Depression, anxiety, sleep problems, pain	NR
Elms, 2019	CBD was tolerated well and not patient discontinued to AE related to CBD	Daytime fogginess, gastrointestinal bloating/pain	N = 10 (48%) withdrew from the trial; authors stated reasons were largely unknown
Jetly, 2015	Cannabis was tolerated well in both arms. Patients experienced mild AE were >50% in both arms	Dry mouth, headache	N = 1 (10%) in the placebo group prior to cross over but no patient dropped out due to AE
Roitman, 2014	Four patients developed AE. These effects were mild and continued throughout the 3 weeks of treatment	Dry mouth, headache, tremor	0
Ruglass, 2017	No AE occurred	AE did not occur at the end of the study	NR